abstract: BACKGROUND: @entity4810 is a @entity74 which affects approximately 10% of couples at childbearing age with substantial clinical and social impact. Genetic variation and environmental factors contribute to susceptibility to @entity73 in @entity1 . The @entity28864 ( @entity28865 ) polymorphism of the autosomal gene, @entity28866 , has shown susceptibility to spermatogenic failure in Taiwanese population. However, no such association has been seen in @entity249 @entity1 from Italy and South India. AIM: This study aims to find out the possible association between @entity28864 ( @entity28865 ) polymorphism of the autosomal gene, @entity28866 and idiopathic @entity4810 in @entity1 from North India. DESIGN: Case-control study. MATERIALS AND METHODS: The prevalence of @entity28864 ( @entity28865 ) polymorphism was determined in 165 idiopathic @entity249 azoo-/oligospermic @entity1 and 200 fertile healthy control @entity1 . PCR-RFLP analysis was employed to determine the genotypes. PCR amplicons were subjected to restriction digestion with AluI as this mutation created a restriction site (AGCT), and separated on a 12% @entity2975 gel. RESULTS: Analysis of 165 idiopathic @entity249 azoo-/oligospermic and 200 fertile control @entity1 revealed only one case of the variant as a heterozygote in the control population. Single Nucleotide Polymorphism (SNP) was absent in the @entity249 @entity1 . CONCLUSION: As in the report from Italy and South India, our results illustrate the rarity of this mutation. Apparently, this mutation is of recent origin and/or has poor selective value. Its preponderance in @entity249 @entity1 from Taiwan (all heterozygotes) suggests a founder effect and also that its low selective value could be due to impaired spermatogenesis.

title: @entity28864 polymorphism of the XXXX gene is not associated with idiopathic @entity4810 in North India.

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'patients', 'men']

entities_list: @entity249 :: ('MESH:D007246', 'Disease') :: ['infertile']

entities_list: @entity4810 :: ('MESH:D007248', 'Disease') :: ['Male infertility', 'male infertility']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['spermatogenic impairment']

entities_list: @entity2975 :: ('CHEBI:51135', 'Chemical') :: ['polyacrylamide']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['multifactorial disorder']

answer: @entity28866 :: (1618,Gene) :: ['DAZL']


abstract: BACKGROUND: The management of @entity5 in the axillary area depends on the etiology of the @entity5 . CASE REPORT: A 37-year-old @entity1 presented with a 2 cm mass in the axillary fossa. Core needle biopsy revealed @entity420 . There were no abnormal breast findings on physical examination, mammography, or ultrasonography. However, enhanced magnetic resonance imaging (MRI) and positron emission tomography (PET) showed a segmentally-distributed, abnormal area in the upper-outer quadrant, continuous with the axillary mass. Samples of this area obtained by vacuum-assisted biopsy showed @entity3821 . These findings indicated that the axillary lesion was a part of primary @entity0 originating from the axillary tail. Based on these results, the @entity1 underwent total mastectomy with sentinel lymph node biopsy. Pathological examination of the specimen showed @entity513 accompanied by @entity3821 extending up to 8.5 cm. Our case suggests that enhanced MRI and PET can provide useful preoperative information for the management of axillary breast lesions.

title: A case of XXXX in the axillary tail of Spence - enhanced magnetic resonance imaging and positron emission tomography for diagnostic differentiation and preoperative treatment decision.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity3821 :: ('MESH:D002285', 'Disease') :: ['intraductal carcinoma']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity513 :: ('MESH:D044584', 'Disease') :: ['invasive ductal carcinoma']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: OBJECTIVE: To review the clinical features and surgical outcome in @entity1 with @entity1315 associated with intractable chronic @entity302 . METHODS: The Rush University Surgical @entity302 Database was queried to identify @entity1 with chronic @entity302 who underwent resection of @entity1315 at Rush University Medical Center. Medical records were reviewed for age of @entity410 onset, delay to referral for surgery, @entity410 frequency and characteristics, pre-operative MRI results, extent of resection, pathological diagnosis, complications, length of follow-up, and @entity410 improvement. RESULTS: Fifteen @entity1 were identified. Average duration between @entity410 onset and surgery was 14.3 years. Complex partial @entity410 were the most common presenting symptom. Detailed operative data was available for 11 @entity1 - of these, 90.9% underwent complete resection of the amygdala and either partial or complete resection of the hippocampus, in addition to lesionectomy. Average follow-up was 10.4 years (range 1.6-27.5 years), with 14 @entity1 improving to Engel's class I and one @entity1 to Engel's class III. There were no recurrences, and permanent complications were noted in one @entity1 . CONCLUSIONS: Long-term follow-up of @entity1 with @entity1315 associated with chronic @entity302 demonstrates excellent results in @entity410 improvement with surgery and increasingly low incidence of complications with improvements in microsurgical techniques.

title: @entity1315 associated with chronic XXXX : long-term surgical outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures']

entities_list: @entity1315 :: ('MESH:D004833', 'Disease') :: ['temporal lobe gangliogliomas']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy', 'intractable epilepsy', 'Epilepsy']

answer: @entity302 :: (MESH:D004827,Disease) :: ['epilepsy']


abstract: UNASSIGNED: @entity1707 (192 total) were blocked by age and stratified by initial BW (25.75    2.29 kg) into pens (2 barrows and 2 gilts per pen). Within blocks, pens were randomly allotted to treatments in a 2 * 2 factorial arrangement, with 2 diet forms (meal vs. pellet) and 2 @entity12360 ( @entity12360 ) inclusion levels (0 vs. 30%). @entity1707 were weighed at the beginning of the experiment and at the end of each feeding phase (d 35, 70, and 91) and daily feed allotments were recorded. @entity1707 were slaughtered at the end of the 91-d experiment, and full gastrointestinal (GI) tract and GI tract component weights were recorded immediately following evisceration. Carcass characteristics and meat quality were determined after a 24-h chill. Overall ADG was increased ( < 0.01) 3.2% when @entity1707 were fed pelleted diets rather than meal diets, but there was no effect ( = 0.46) of @entity12360 inclusion on overall ADG. Overall ADFI of meal-fed @entity1707 fed 30% @entity12360 was 4.7% greater ( < 0.01) than that of @entity1707 fed 0% @entity12360 in meal form, but overall ADFI did not differ ( >=  0.19) between @entity12360 inclusion level in pellet-fed @entity1707 (diet form * @entity12360 inclusion, < 0.01). When fed meal diets, @entity1707 fed 0% @entity12360 had 2.7% greater ( = 0.02) overall G:F than @entity1707 fed 30% @entity12360 ; however, there was no difference ( = 0.42) in overall G:F between @entity12360 inclusion levels in @entity1707 fed pelleted diets (diet form * @entity12360 inclusion, < 0.03). @entity1707 fed pelleted diets had 2.9% heavier HCW ( = 0.01), 10.4% greater 10th-rib back fat ( = 0.01), and 1.8 percentage units less estimated lean percentage ( = 0.04) than meal-fed @entity1707 . Full GI tracts of @entity1707 fed pelleted diets were 0.33 percentage units less ( = 0.03) of the ending live weight than that of meal-fed @entity1707 due to decreased ( < 0.01) GI tract contents. Inclusion of @entity12360 increased ( = 0.03) full GI tract weight, large intestine weight ( < 0.01), and GI tract contents ( = 0.02). Severity of @entity8286 of the pars esophagea was greater ( < 0.01) in pellet-fed @entity1707 than in meal-fed @entity1707 , but the magnitude of the difference was likely not great enough to negatively affect drop credit of stomachs. In conclusion, feeding pelleted diets improved growth performance and increased carcass weight and @entity1386 without causing the development of @entity1819 that would reduce the value of the stomach to packers. Furthermore, inclusion of @entity12360 in diets reduced HCW and dressing percent and increased GI tract and GI tract contents weight but had no effect on @entity1819 development or LM quality.

title: Effects of pelleting diets without or with XXXX on growth performance, carcass characteristics, and gastrointestinal weights of growing-finishing barrows and gilts.

entities_list: @entity1819 :: ('MESH:D013272', 'Disease') :: ['gastric lesions', 'gastric lesion']

entities_list: @entity8286 :: ('MESH:D010241', 'Disease') :: ['parakeratosis']

entities_list: @entity12360 :: ('MESH:C565532', 'Disease') :: ["distillers' dried grains with solubles", 'DDGS']

answer: @entity12360 :: (MESH:C565532,Disease) :: ['distillers' dried grains with solubles']


abstract: Aortopulmonary (AP) window is a communication between the ascending aorta and the main pulmonary artery, in the presence of two separate arterial valves arising from separate subarterial ventricular outflow tracts. It is a rare @entity154 that accounts for approximately 0.1% to 0.2% of all @entity299 . The purpose of this study was to assess clinical features, surgical treatment and outcome of @entity1 with @entity2009 referred to a tertiary pediatric cardiac center over a 30-year period. Eleven @entity1 were diagnosed with AP window, ten with the proximal type and one with the distal type defect. Age at first evaluation ranged from three days to 13 years (mean 44.5+/-63.3 months; median three months). Echocardiography enabled correct diagnosis in the four most recent cases. Seven @entity1 underwent closure of the AP window through a transaortic approach and three @entity1 underwent ligation. Simultaneously, significant associated @entity299 were corrected in three @entity1 : correction of interrupted aortic arch in two @entity1 and closure of @entity1757 and Dacron patch enlargement of the right ventricular outflow tract in one @entity1 . One @entity1 was not operated because of fixed high pulmonary vascular resistance. Operative mortality was 10% (1/10) and there were no late deaths. Mean follow-up was 10+/-4.9 years. All nine surviving operated @entity1 are asymptomatic, without medication, with no residual defects and without @entity120 . In conclusion, advances in diagnostic and surgical approaches to AP window in recent years have enabled earlier intervention with good outcome.

title: XXXX . Experience of eleven cases.

entities_list: @entity2009 :: ('MESH:C537782', 'Disease') :: ['aortopulmonary window']

entities_list: @entity1757 :: ('MESH:D006345', 'Disease') :: ['ventricular septal defect']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac anomalies', 'congenital heart disease']

answer: @entity2009 :: (MESH:C537782,Disease) :: ['Aortopulmonary window']


abstract: INTRODUCTION: @entity910 ( @entity910 ) is a rare genetically heterogenous condition. Mutations in @entity4594 or @entity27520 genes can be found in about a third of the @entity1 with @entity910 . Increased occurrence of mutations was described in several exons of these long genes. The objective of the study was to test the sensitivity of sequencing of selected 13 exons (as compared to costly sequencing of all 100 exons of the two genes), and to determine the prevalence of the @entity4594 or @entity27520 mutations in the Czech @entity910 database. METHODS: The Czech national @entity910 database has identified 31 pediatric @entity1 , diagnosed based on clinical findings and tests on the ciliated epithelium. Twenty-seven @entity1 from 24 families agreed on genetic testing. In the first step, direct sequencing of selected 13 exons (9 of @entity4594 of @entity27520 ) was performed, and then we compared its effectiveness in detecting at least one mutation with results of sequencing all 100 exons of the two genes. RESULTS: The sequencing of all exons identified compound heterozygosity for @entity910 mutations in nine @entity1 from eight families ( @entity4594 in eight and @entity27520 in one @entity1 ), and heterozygozity for a @entity4594 mutation of uncertain functional significance in one additional @entity1 . The first step of selected exon sequencing detected a mutation in five out of these eight families, its actual sensitivity being 62.5%, with a high predictive value. The phenotypic and clinical characteristics of all the paediatric @entity1 with @entity910 are shown. CONCLUSIONS: Selected exon sequencing detects at least one mutated allele in over a half of our @entity1 who have @entity910 due to @entity4594 or @entity27520 mutations. To lower the costs of the genetic testing, targeted step-wise genetic testing may be a reasonable approach to detect mutations in @entity910 @entity1 , especially if their phenotype is taken into account.

title: Effectiveness of sequencing selected exons of XXXX and @entity27520 in diagnosis of primary @entity910 .

entities_list: @entity910 :: ('MESH:D004409', 'Disease') :: ['PCD', 'Primary ciliary dyskinesia']

answer: @entity4594 :: (1767,Gene) :: ['DNAH5']


abstract: 1. Agonists known to increase @entity1919 levels in gastrointestinal smooth muscles were studied in isolated circular muscles of the @entity235 antrum to investigate the mechanisms of the inhibitory effects of these agents. 2. Muscles were electrically active, generating typical slow wave activity. Cytosolic Ca2+ ([Ca2+]cyt; measured by Indo-1 fluorescence) and tension increased in response to slow waves. 3. Stimulation by @entity3044 (via beta 2-receptors) or @entity1928 , in the presence or absence of @entity934 , inhibited the plateau phase and reduced phasic [Ca2+]cyt and contractile responses. 4. Vasoactive intestinal peptide ( @entity10299 ) and calcitonin gene-related peptide (CGRP), had similar effects to @entity3044 and @entity1928 . 5. Increases in the plateau phase of slow waves and the associated increases in [Ca2+]cyt and tension caused by direct activation of voltage-dependent Ca2+ channels by @entity9898 (0.1 microM) were also reduced by @entity1928 . 6. @entity3044 and @entity1928 induced negative chronotropic effects, but @entity10299 increased frequency. 7. At a given level of [ @entity141 ]cyt, contractions were greater under control conditions than in the presence of @entity3044 , @entity10299 and CGRP, suggesting that part of the inhibition produced by these agents may be due to decreased Ca2+ sensitivity of the contractile apparatus. 8. Experiments performed on alpha-toxin-permeabilized muscles confirmed that @entity1919 -dependent effects involve reduced Ca2+ sensitivity of the contractile apparatus. Addition of @entity1919 (3-300 microM) caused a reduction in @entity141 -induced contraction at a constant level of Ca2+ (pCa 5.5). 9. These results suggest that increased @entity1919 and probably subsequent activation of protein kinase A: (i) decrease [Ca2+]cyt and contraction by an inhibition of Ca2+ influx during slow waves, and (ii) decrease the sensitivity of the contractile apparatus to [Ca2+]cyt. The membrane effects might occur directly by inhibition of Ca2+ channels or indirectly by increasing the open probability of @entity3529 channels which would tend to cause premature repolarization of slow waves.

title: XXXX -mediated regulation of excitation-contraction coupling in @entity235 gastric smooth muscle.

entities_list: @entity1919 :: ('MESH:D000242', 'Chemical') :: ['cyclic AMP']

entities_list: @entity3044 :: ('MESH:D007545', 'Chemical') :: ['Isoprenaline', 'isoprenaline']

entities_list: @entity1928 :: ('MESH:D005576', 'Chemical') :: ['forskolin']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity1919 :: (MESH:D000242,Chemical) :: ['Cyclic AMP']


abstract: BACKGROUND: Recent studies have shown a correlation between @entity1669 and @entity1377 of the thyroid. It is thought that @entity1669 could be a risk factor for the development of @entity259 , mainly for the papillary variant. CASE: A 59-year-old female presented with a history of @entity135 and five months of @entity1282 . Clinical examination showed generalized expansion and an increase in the hardness of the thyroid gland. Hormonal outline showed @entity1375 with serum levels of TSH slightly elevated (5 micrograms/dL; range, 0.25-4). Thyroglobulin antibodies and @entity5787 titers were moderately positive. Given these results, a diagnosis of @entity10972 was made. Thyroid ultrasound scan showed diffuse gland irregularity and the presence of a solitary nodule (2.3 cm in diameter) localized in the right lobe. Fine needle aspiration biopsy (FNAB) of the nodule was performed under ultrasound guidance. CONCLUSION: Although clinical and laboratory results supported the diagnosis of @entity1669 only, FNAB of the nodular lesion provided evidence of a rare case of @entity1377 , tall cell variant, confirmed by histologic results.

title: Tall cell variant of XXXX coexisting with chronic lymphocytic thyroiditis. A case report.

entities_list: @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary carcinoma']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['enlargement in the neck']

entities_list: @entity1375 :: ('MESH:D007037', 'Disease') :: ['subclinical hypothyroidism']

entities_list: @entity5787 :: ('7173', 'Gene') :: ['thyroperoxidase']

entities_list: @entity1669 :: ('MESH:D013967', 'Disease') :: ['autoimmune thyroiditis', 'lymphocytic thyroiditis']

entities_list: @entity10972 :: ('MESH:C535842', 'Disease') :: ['chronic thyroiditis']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia']

entities_list: @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid carcinoma']

answer: @entity1377 :: (MESH:D002291,Disease) :: ['papillary carcinoma']


abstract: A simple and specific high-performance liquid chromatographic (HPLC) method was developed for the pharmacokinetic study of @entity21543 ( @entity4306 , isolated from the leaves of Crataegus pinnatifida Bge. var. major) in @entity35 after intravenous administration. The plasma samples were deproteinized with @entity1042 after addition of internal standard (I.S.), @entity7651 . HPLC analysis was performed on a Diamonsil C18 analytical column, using @entity1042 -0.6% aqueous @entity8718 (45:55, v/v) as the mobile phase with UV detection at 340 nm. The calibration curve was linear over the range of 0.8921-59.7125 microg/ml in @entity35 plasma. The average extraction recovery of @entity4306 was 99.33+/-0.86%, and the relative standard deviations (R.S.D.s) of the intra- and inter-day precisions were no more than 7.8 and 2.5%, respectively. The lower limit of quantification (LLOQ) was 0.8921 microg/ml. The validated method was successfully applied during a pharmacokinetic study in @entity35 after intravenous administration of @entity4306 at different doses, and all the results indicated that the pharmacokinetics of @entity4306 in @entity35 obeyed nonlinear processes.

title: LC determination and pharmacokinetic study of XXXX in @entity35 plasma after intravenous administration.

entities_list: @entity8718 :: ('MESH:C030242', 'Chemical') :: ['phosphoric acid']

entities_list: @entity1042 :: ('MESH:D000432', 'Chemical') :: ['methanol']

entities_list: @entity7651 :: ('MESH:C038044', 'Chemical') :: ['baicalin']

entities_list: @entity21543 :: ('MESH:C021304', 'Chemical') :: ['hyperoside']

answer: @entity21543 :: (MESH:C021304,Chemical) :: ['hyperoside']


abstract: @entity2998 @entity850 is an important cause of transient ischaemic attacks (TIAs) and @entity64 , and is associated with a particularly high risk of recurrent @entity64 both in the acute phase and the long-term. Early secondary preventive measures would therefore seem warranted. Carotid endarterectomy (CEA) is an effectively therapy in @entity1 with a severe symptomatic @entity850 . @entity101 is an important risk factor for recurrent @entity64 both in the acute phase and the long-term. Moreover, @entity101 is an important risk factor for complications of CEA. In @entity1 on the waiting list for CEA, following a @entity4905 or a non-disabling @entity64 , it would seem worthwhile to attempt to start antihypertensive treatment after approximately 24 h, and to at least strive after a preoperative systolic blood pressure of < 180 mmHg and a diastolic blood pressure of < 90 mmHg. In @entity1 who cannot undergo surgery in the desirable short run, @entity551 treatment must be considered in the context of secondary prevention. The blood pressure target level depends on the presence or absence of a severe unilateral or bilateral @entity850 (> 70% lumen diameter). In postoperative @entity101 one must strive after a blood pressure < 140/90 mmHg, thereby avoiding an excessively rapid @entity551 response (> 25% daily). @entity1 with a @entity4905 or an @entity64 and a @entity543 must also be treated with antiplatelet agents and a statin, while other vascular risk factors must be controlled.

title: [Blood pressure control in @entity1 with a symptomatic XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'ischaemic stroke', 'ischaemic strokes']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'Hypertension']

entities_list: @entity2998 :: ('MESH:D002340', 'Disease') :: ['Carotid artery']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotensive']

entities_list: @entity543 :: ('MESH:D016893', 'Disease') :: ['carotid artery stenosis']

answer: @entity543 :: (MESH:D016893,Disease) :: ['carotid artery stenosis']


abstract: BACKGROUND: @entity14 ( @entity14 ) is one of the most common @entity5 worldwide. The majority (approximately 60%) of @entity1 with @entity14 will eventually develop liver @entity3 , which remain the most common cause of mortality in these @entity1 . This study aimed to evaluate the therapeutic effect and tolerability of gelatin sponge particle (GSP)-mediated chemoembolization in the treatment of colorectal liver @entity3 after systemic chemotherapy failure. METHODS: This was a single-center retrospective study of 15 @entity1 with colorectal liver @entity3 , who underwent GSP-mediated chemoembolization with 50 mg of @entity13750 during the period December 2009 to December 2010 in the Department of Interventional Radiology, Affiliated Zhongshan Hospital of Dalian University. Clinical data were retrieved, and the therapeutic effect and tolerability of the treatment were evaluated. RESULTS: All 15 @entity1 with colorectal liver @entity3 completed the GSP-mediated chemoembolization. The therapeutic effect and tolerability were evaluated 3 months after the initial procedure. The @entity5 lesions in all @entity1 showed various levels of @entity39 and shrinkage. According to the Response Evaluation Criteria in @entity5 (RECIST), one @entity1 achieved complete response (CR), eleven @entity1 achieved partial response (PR), and three @entity1 achieved @entity66 ( @entity66 ). The overall response rate (CR   +   PR) was 80%. CONCLUSIONS: GSP-mediated chemoembolization is well tolerated and has a good short-term response rate (80%) in the treatment of colorectal liver @entity3 after systemic chemotherapy failure. Collectively, further study of the long-term effect of GSP-mediated chemoembolization in @entity14 in a large cohort is warranted.

title: Therapeutic effect and tolerability of gelatin sponge particle-mediated chemoembolization for colorectal liver XXXX : a retrospective study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['stable disease', 'SD']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Solid Tumors', 'cancers']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['Colorectal cancer', 'CRC', 'colorectal liver metastasis']

entities_list: @entity13750 :: ('MESH:C066228', 'Chemical') :: ['lobaplatin']

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastases']


abstract: BACKGROUND/AIM: In addition to medical advice, telemedical centers also provide counseling on the telephone for @entity1 with @entity8495 . MATERIAL AND METHODS: Data from a Swiss telemedical center during the years 2001-2008 were analyzed retrospectively. RESULTS: A total of 371 988 medical consultations were recorded. Of these, 3430 concerned dental problems, with 672 reports about dental @entity130 following accidents with 772 injuries. The @entity1 average age was 8.6 years (range 0-73 years). About two-thirds of the cases belonged to the age group 0-6 years, and one-third to the group of 7-80 years. The reasons for calling were dislocations (53%), @entity174 (31.9%), and @entity155 (7.9%). In 76.2% of the cases, the center was contacted on the day of the accident. The majority of the @entity1 (60%) contacted the telemedical center during the so-called 'out of office hours' (Monday to Friday 6 pm to 8 am, and Saturday/Sunday all day). CONCLUSIONS: Telemedicial services can be helpful for cases related to dental @entity130 and may provide valuable support when a dentist is not available.

title: Teledental consultations related to XXXX in a Swiss telemedical center: a retrospective survey.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures']

entities_list: @entity8495 :: ('MESH:D018677', 'Disease') :: ['dental injuries']

entities_list: @entity155 :: ('MESH:D014084', 'Disease') :: ['avulsions']

answer: @entity130 :: (MESH:D014947,Disease) :: ['trauma']


abstract: @entity8654 are related to paroxysmal or chronic @entity713 (50-60%), sinoatrial (SA) block (30-40%) or @entity591 (0-5%). In between attacks most @entity1 present with sinus rhythm, a large part with widened QRS complex. A minor proportion of @entity1 present with chronic @entity713 . ECG is very rarely normal. Diagnosis is based on ECG recording during fainting. In @entity1 with sinus rhythm and @entity5036 or @entity713 , ECG monitoring should be performed in hospital, since @entity8654 in these @entity1 is a potentially life-threatening disease. In @entity1817 where the suspected @entity943 is not life-threatening, ambulatory ECG by Holter monitoring can be performed to establish the diagnosis. In cases where ECG monitoring leaves doubt, an electrophysiologic study including His bundle electrography and sinus node recovery time may support the diagnosis, although normal findings do not preclude the diagnosis. Pacemaker implantation should be performed in @entity8654 , as oral drug treatment is ineffective. The dual-chamber pacemaker presents the advantages of both physiological heart rate and AV synchrony, but has troublesome side effects. Most @entity1 with @entity591 / @entity1168 syndromes require supplementary anti-arrhythmic treatment, and in some @entity1 additional long-term anticoagulation should be considered.

title: Management of XXXX .

entities_list: @entity8654 :: ('MESH:D000219', 'Disease') :: ['Stokes-Adams attacks', 'Stokes-Adams syndrome']

entities_list: @entity713 :: ('MESH:D054537', 'Disease') :: ['AV block', 'atrioventricular (AV) block']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardia', 'paroxysmal tachycardia or fibrillation']

entities_list: @entity1817 :: ('MESH:D012804', 'Disease') :: ['sick sinus syndrome']

entities_list: @entity5036 :: ('OMIM:113900', 'Disease') :: ['bundle-branch block']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia']

entities_list: @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradycardia']

answer: @entity8654 :: (MESH:D000219,Disease) :: ['Stokes-Adams syndrome']


abstract: INTRODUCTION: Treatment of @entity1 with @entity1985 ( @entity1985 ) caused by @entity8 has no consensus therapy. OBJECTIVES: This is a retrospective analysis (RA), performed on 55 @entity1 with @entity1985 treated during one year with enteric coated @entity618 (EC-MPS) and reduced corticosteroids doses. MATERIAL AND METHODS: Inclusion criteria for this RA were: @entity1 aged >=  18 years old, diagnosed with @entity1985 with histologically proven @entity8 who had received standard therapy with @entity4688 and/or @entity9886 and 10 mg per day or 20 mg of @entity229 every other day. NS was defined with the following criteria: @entity644 > 3.5 g/day, serum albumin  <= 3 g/dl, @entity1007 and @entity4 . Treatment consisted of oral EC-MPS in 360 mg tablets, 720 mg bid, together with @entity229 10 mg daily or 20 mg every other day. Effectiveness was assessed as the rate of response in the cohort: complete, partial or absent. Complete response @entity1 : 24 hours @entity644 < 300 mg/day, partial response @entity1 : @entity644 > 300 mg/day and < than 3 g/day, all the rest were considered as non responders. RESULTS: response was achieved in 40/55 (73%) of @entity1 , 24 (44%) with complete response and 16 (29%) with partial response. No EC-MPS discontinuation has been observed due to adverse events, except for one case of transient interruption of medication for 2 weeks. CONCLUSION: EC-MPS as single therapy with minimal doses of @entity288 as in this RA could be an effective alternative in the treatment of @entity1 with @entity1985 .

title: Use of enteric coated mycophenolate sodium in adult resistant XXXX .

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['glomerulopathies', 'glomerulopathy']

entities_list: @entity4688 :: ('MESH:D004656', 'Chemical') :: ['enalapril']

entities_list: @entity1007 :: ('MESH:D006937', 'Disease') :: ['hypercholesterolemia']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity9886 :: ('MESH:D019808', 'Chemical') :: ['losartan']

entities_list: @entity618 :: ('MESH:C063008', 'Chemical') :: ['sodium mycophenolate']

entities_list: @entity1985 :: ('MESH:D009404', 'Disease') :: ['resistant/relapsed adult nephrotic syndrome', 'RNS']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity1985 :: (MESH:D009404,Disease) :: ['nephrotic syndrome']


abstract: Our study focuses to determine the medium range results of function and radiological findings of operatively treated @entity174 of the talus. Furthermore we had the intention to investigate risk-factors for posttraumatic @entity4040 and @entity39 of the talus. MATERIAL AND METHODS: We included all 41 @entity1 (w/m: 13/28) operated between 1995-2000 with talus neck, corpus or dislocated @entity174 of the talus edge (open/closed: 11/30). @entity174 were classified according to Hawkins: type 1: 6 x, type II: 17 x, type III: 7 x, type IV: 3 x, 8 x dislocated peripheral @entity174 . 39 x screw osteosynthesis, 2 x K-wire fixation were done and 12 additive transfixation with fixateur externe. Score: AOFAS Ankle-Hindfoot-Scale, radiological assessment according to the Bargon score. 34 @entity1 , mean age 35 years (12-60), were followed up clinically with an average of 4 years (24-72 months). RESULTS: AOFAS Score: pain (40 points): diameter 31 [10-40]; function (50 points): diameter 39 [14-50]; alignement (10 points):diameter 7 [0-10]; degree of @entity625 due to the Bargon scale: 0 degree: 5x,1 degree: 8x, 2 degrees: 7 x, 3 degrees: 7 x. COMPLICATIONS: 4 x @entity39 of margin of the wound, 1 @entity281 , 5 @entity39 of the talus bone. The severity of the @entity174 was 1 x type II according to Hawkins 3 x type III and 1 x type IV. 3 of the 5 @entity1 who developed a @entity39 had 28 or 38 soft tissue damage. One @entity1 had an imminent @entity2054 . One @entity1 who suffered a @entity1230 was operated six days post injury. Second operation: 1 Syme amputation due to @entity39 of the talus subsequent to an @entity281 . 4 x arthrodesis of the upper ankle joint and 5 x arthrodesis of the subtalar joint due to posttraumatic @entity625 . CONCLUSION: Primary screw osteosynthesis is the treatment of choice depending on the lesions of the soft-tissue and accompanied injuries in combination with a fixateur externe. Nevertheless the primary osteosynthesis is not able to prevent @entity39 of the talus completely, that occurs in a frequency of 15%. Risk factors for a posttraumatic @entity625 in addition to the type of @entity174 and the result of reconstruction are an accompanied soft tissue defect and local capsule-band complex with necessary temporary transfixation. Early plastic reconstruction of defects can reduce the time of immobilisation and allows motion therapy. The functional results are positive compared with the radiological results that showed @entity625 in 70%.

title: [What are the clinical results of operated XXXX of the talus?].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'Fractures', 'fracture']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['talus necrosis', 'necrosis']

entities_list: @entity4040 :: ('MESH:C537208', 'Disease') :: ['arthrosis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'deep infection']

entities_list: @entity2054 :: ('MESH:D003161', 'Disease') :: ['compartment syndrome']

entities_list: @entity1230 :: ('MESH:D009104', 'Disease') :: ['polytrauma']

answer: @entity174 :: (MESH:D050723,Disease) :: ['fractures']


abstract: The purpose of this study is to clarify signal transduction of expression of the @entity2071 ( @entity2071 ) via @entity2936 - @entity2936 ligand in salivary glands of @entity1 with @entity244 ( @entity244 ). We used cultured salivary gland epithelial cells (SG cells) from 15 @entity244 @entity1 and 8 controls obtained by labial minor salivary gland biopsy. First, @entity2071 expression was determined with reverse transcriptase-polymerase chain reaction and flow cytometry in the presence or absence of soluble @entity11603 (sCD40L). Next, SG cells were transfected with plasmids of pGL1.3-Luc inserted with promoter region of @entity2071 , pGL1.3kB(-)-Luc mutated in @entity2451 ( @entity2451 ) binding site of pGL1.3-Luc and pNF-kappaB-Luc by lipofection method. Luciferase activity of the cells was measured in the presence or absence of sCD40L or sCD40L and an @entity2451 inhibitor, @entity13373 ( @entity14568 ). Finally @entity2451 family proteins of cell nuclear extracts were determined. @entity2071 expression was significantly enhanced with sCD40L at the mRNA and protein level. Activity of pNF-kappaB-Luc and pGL1.3-Luc was significantly elevated by stimulation with sCD40L and suppressed by @entity14568 . @entity2451 protein level was elevated by stimulation with sCD40L and suppressed by @entity14568 . Our results suggest that sCD40L enhances the @entity2071 expression by activation of @entity2451 in the @entity244 SG cells.

title: @entity2936 - @entity2936 ligand signal induces the @entity2071 expression through nuclear factor-kappa B p50 in cultured salivary gland epithelial cells from @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2451 :: ('4790', 'Gene') :: ['nuclear factor kappa-B', 'NF-kappaB', 'NF-kappaB p50']

entities_list: @entity13373 :: ('MESH:C020972', 'Chemical') :: ['pyrrolidine dithiocarbamate']

entities_list: @entity244 :: ('MESH:D014899', 'Disease') :: ["Sj  gren's syndrome", 'SS']

entities_list: @entity2071 :: ('3383', 'Gene') :: ['ICAM-1', 'intercellular adhesion molecule-1']

answer: @entity244 :: (MESH:D014899,Disease) :: ['Sj  gren's syndrome']


abstract: BACKGROUND: The @entity28 epidemic disproportionately affects Hispanics. This paper reports on the design of the ongoing Healthy Families Study, a randomized controlled trial testing the efficacy of a community-based, behavioral family intervention to prevent excessive @entity1017 in Hispanic @entity1 using a community-based participatory research approach. METHODS: The study will enroll 272 Hispanic families with @entity1 ages 5-7 residing in greater Nashville, Tennessee, United States. Families are randomized to the active @entity1017 prevention intervention or an alternative intervention focused on oral health. Lay community health promoters implement the interventions primarily in Spanish in a community center. The active intervention was adapted from the We Can! parent program to be culturally-targeted for Hispanic families and for younger @entity1 . This 12-month intervention promotes healthy eating behaviors, increased physical activity, and decreased sedentary behavior, with an emphasis on parental modeling and experiential learning for @entity1 . Families attend eight bi-monthly group sessions during four months then receive information and/or support by phone or mail each month for eight months. The primary outcome is change in @entity1 's body mass index. Secondary outcomes are changes in @entity1 's waist circumference, dietary behaviors, preferences for fruits and vegetables, physical activity, and screen time. RESULTS: Enrollment and data collection are in progress. CONCLUSION: This study will contribute valuable evidence on efficacy of a @entity28 prevention intervention targeting Hispanic families with implications for reducing disparities.

title: Healthy families study: design of a XXXX prevention trial for Hispanic families.

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['childhood obesity']

answer: @entity28 :: (MESH:D009765,Disease) :: ['childhood obesity']


abstract: 1. A re-investigation of the kinetics of @entity375 @entity21590 in the direction of @entity35798 formation has been carried out, covering a 1000-fold range in substrate concentrations. A variety of improved spectrophotometric and fluorimetric assay procedures have been used. 2. Kinetic plots proved to be non-linear for each variable substrate. A variety of checks have been carried out to show that this is not due to artifacts in the assay procedures or heterogeneity of the enzyme preparation. 3. The effects of a variety of salts on the activity of the enzyme have been examined. Most salts, especially those with multivalent anions, can cause activation of the enzyme, but inhibit at high concentration. 4. The salt effect is shown to be principally due to anions rather than cations, and not to ionic strength changes. @entity597 , as one of the most effective anions has been used in most comparisons. 5. Salt activation is steepest when the substrate concentrations are low; maximum activation has been about 5-fold with 0.2 mM @entity855 and 0.2 mM @entity10254 . Inhibition at the higher salt concentrations is strongest at the same substrate concentrations as when activation is steepest, indicating a link between the two effects. 6. The presence of 20 mM or more @entity2398 converted non-linear kinetic plots to linear ones. A study of the kinetics in the presence of 40 mM @entity2398 was interpreted in terms of a random sequential binding mechanism, with @entity597 acting as a competitive inhibitor. 7. Possible explanations for these anomalous results are discussed in terms of several mechanisms which have been shown to apply in other systems.

title: The steady-state kinetics of @entity375 XXXX . Anomalous kinetic plots and the effects of salts on activity.

entities_list: @entity35798 :: ('MESH:C015891', 'Chemical') :: ['1,3-bisphosphoglycerate']

entities_list: @entity10254 :: ('MESH:C005156', 'Chemical') :: ['3-phosphoglycerate']

entities_list: @entity21590 :: ('850370(Tax:4932)', 'Gene') :: ['phosphoglycerate kinase']

entities_list: @entity597 :: ('CHEBI:16189', 'Chemical') :: ['Sulphate', 'sulphate']

answer: @entity21590 :: (850370(Tax:4932),Gene) :: ['phosphoglycerate kinase']


abstract: BACKGROUND: @entity534 is an important precursor of @entity842 (NO) and protein synthesis. @entity369 is produced in the body (mainly kidney) by de novo production from @entity7792 and by protein breakdown. @entity369 availability appears to be limited in @entity295 . OBJECTIVE: The objective was to compare @entity369 and @entity7792 metabolism in septic @entity1 and nonseptic control @entity1 in an intensive care unit (ICU) and in healthy control subjects. DESIGN: Ten @entity1 with @entity326 , 7 critically ill control @entity1 , and 16 healthy elderly subjects were studied. Metabolism was measured by using a primed continuous (2 h) stable-isotope infusion protocol. NO production was calculated as the conversion rate of @entity369 to @entity7792 ; de novo @entity369 production was calculated as the conversion rate of @entity7792 to @entity369 . Arterial blood (arterialized venous blood in healthy subjects) was collected for the measurement of @entity535 enrichment and concentrations. Data are reported as means +/- SDs. RESULTS: Whole-body @entity7792 production was significantly lower in septic @entity1 (4.5 +/- 2.1 micromol . kg(-1) . h(-1)) than in ICU control @entity1 (10.1 +/- 2.9 micromol . kg(-1) . h(-1); P < 0.01) and in healthy control subjects (13.7 +/- 4.1 micromol . kg(-1) . h(-1); P < 0.001). Accordingly, de novo @entity369 production was lower in @entity1 with @entity295 (3.3 +/- 3.7 micromol . kg(-1) . h(-1)) than in healthy controls (11.9 +/- 6.6 micromol . kg(-1) . h(-1); P < 0.01) and tended to be lower in septic @entity1 than in ICU control @entity1 (10.9 +/- 9.4 micromol . kg(-1) . h(-1); P = 0.05). NO production was lower in septic @entity1 than in healthy control subjects (P < 0.01), whereas a larger part of @entity369 was converted to @entity1133 in @entity295 . CONCLUSIONS: @entity7792 production is severely low in @entity1 with @entity295 and is related to diminished de novo @entity369 and NO production. These metabolic alterations contribute to reduced @entity7792 and @entity369 availability, and these findings warrant further studies of therapeutic nutritional interventions to restore @entity369 metabolism in @entity295 .

title: Reduced @entity7792 production in @entity295 is related to diminished de novo @entity369 and XXXX production.

entities_list: @entity7792 :: ('CHEBI:16349', 'Chemical') :: ['citrulline', 'Citrulline']

entities_list: @entity326 :: ('MESH:D012772', 'Disease') :: ['septic shock']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity534 :: ('CHEBI:16467', 'Chemical') :: ['L-Arginine']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity369 :: ('CHEBI:29016', 'Chemical') :: ['arginine', 'Arginine']

answer: @entity842 :: (MESH:D009569,Chemical) :: ['nitric oxide']


abstract: The results of operative treatment of postinfarction @entity1002 in 169 @entity1 undergoing operation since 1970 are analyzed in this report. Maximum follow-up extended to 7 year (average 2.9 years). Average @entity1 age was 56 years (range 34 to 82 years). Nearly all @entity1 (94%) had left anterior descending coronary artery disease with anterior @entity439 formation and 73% had multivessel disease. Sixty-eight percent of @entity1 underwent aorta-coronary bypass grafting (ACBG) and/or mitral valve replacement (MVR) concomitantly with aneurysmectomy. The over-all operative mortality rate was 17.8%. Preoperative factors that correlated significantly (p less than 0.05) with increased operative risk reflected primarily the quality of left ventricular function, and included functional classification, cardiac index, contractile function of residual myocardium not involved by @entity439 , and @entity339 . @entity1 whose primary @entity717 consisted of @entity951 (42 @entity1 ) exhibited significantly higher over-all survival rates (actuarial 5 year survival 75%) than those undergoing operation because of @entity712 (86 @entity1 ) or @entity1165 (38 @entity1 ), whose 5 year survival rates were 52 and 57%, respectively. Concomitant ACBG (+/- MVR) was associated with a higher operative mortality rate than aneurysmectomy alone (21.1 versus 10.9%), but late postoperative attrition was similar. The over-all 5 year survival rate, including operative @entity204 , was 60%, and 90% of surviving @entity1 were in Functional Class I or II at follow-up evaluation. We conclude from this analysis that the long-term prognosis of @entity1 with symptomatic postinfection left @entity439 , although determined importantly by preoperative left ventricular function, is enhanced by surgical treatment.

title: XXXX . Preoperative risk factors and long-term postoperative results.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure']

entities_list: @entity339 :: ('MESH:D008944', 'Disease') :: ['mitral regurgitation']

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachyarrhythmias']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['ventricular aneurysms', 'aneurysm']

entities_list: @entity951 :: ('MESH:D000787', 'Disease') :: ['angina pectoris']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['preoperative disability']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['left ventricular aneurysm']

answer: @entity1002 :: (MESH:D018487,Disease) :: ['Left ventricular aneurysm']


abstract: INTRODUCTION: The outcome of @entity174 due to large aggressive benign stage 3 Dormans and Flynn lesions [6] is often unsatisfactory and the rate of recurrence is high. No single technique has been considered safe and successful. Many Authors suggested curettage and bone grafting as the unique effective treatment in cases of large defect but, because of the invasive and complex nature of the operation (it needs a double-step procedure), it is not preferred. The purpose of this study is to examine the effectiveness of a minimally invasive treatment in one step through ESIN, curettage and packing with self-setting @entity78 cement. @entity1 AND METHODS: This is a retrospective study of 116 @entity1 admitted at the Division of Pediatric Orthopaedics Surgery of Santobono @entity1 Hospital between 2006 and 2014 with a diagnosis of @entity174 due to large aggressive ostheolytic benign lesions (stage 3 Dormans and Flynn). The size of @entity604 was measured on the AP and ML radiographs and all the cysts with a caudo cranial extension from 5 to 8cm and with a medio lateral extension from 3 to 5cm were included. Mean time follow up 24 months was performed. RESULTS: The three-in-one procedure was applied in all 116 @entity1 . After two years of follow up, 113 @entity1 were classified as healed and just 3 required 3 years to complete heal. No severe life threatening adverse effects or complications associated with the use of ESIN and injectable HA were recorded during the follow up period of 24-36 months. @entity174 healing occurred in all cases within 4-6 weeks with adequate periosteal and endosteal callus formation. No second @entity174 occurred in our series as well as no cysts reoccurred. @entity1 with humeral localizations showed a more rapid regain of muscular function and reestablishment of a complete range of motion. CONCLUSIONS: The proposed three-in-one procedure has shown to be efficient, cost-effective, associated to high rates of definitive bone healing and low incidence of adverse effects.

title: "Three-in-One minimally invasive approach to surgical treatment of pediatric @entity174 with wide XXXX through bone cysts: ESIN, curettage and packing with injectable HA bone substitute. A retrospective series of 116 cases."

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients', 'Children', 'PATIENTS']

entities_list: @entity78 :: ('MESH:C020243', 'Chemical') :: ['calcium phosphate']

entities_list: @entity604 :: ('MESH:D016301', 'Disease') :: ['bone loss']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['pathological fracture', 'Fracture', 'pathological fractures']

answer: @entity604 :: (MESH:D016301,Disease) :: ['bone loss']


abstract: OBJECTIVES: The main aims of treatment in @entity1 with @entity613 ( @entity613 ) are to improve the clinical indicators of lower limb ischaemia and @entity1 ' quality of life (QoL). The aims of this study were assess the clinical and cost effectiveness of a @entity7047 ( @entity7047 ) in @entity1 with @entity613 . DESIGN: Non-randomised, controlled trial. SETTING: University teaching hospital. @entity1 AND METHODS: Two groups of @entity1 with @entity613 were studied. Seventy @entity1 were sequentially recruited before and after the establishment of a Supervised Exercise Programme at our unit. Thirty-seven @entity1 (median age 69 years, 26 @entity1 ) received @entity910 ( @entity910 ) and 33 @entity1 (median age 67 years, 22 @entity1 ) received @entity910 plus a 3 month @entity7047 of graduated physical exercise for sixty minutes, three times each week. @entity1 were assessed prior to and at 6 months following treatment. At each assessment @entity1 reported walking distances (PRWD), treadmill @entity613 and maximal distances ( @entity1479 and MWD), ankle brachial pressure indices (ABPI) pre _ post exercise and @entity1 reported QoL using the SF36 questionnaire were assessed. RESULTS: Prior to intervention the two groups were well matched. Following treatment, @entity910 @entity1 demonstrated no significant change in PRWD or @entity1479 but did record a small but significant improvement in MWD. @entity910 was also associated with a negative effect size in the SF36 index and in 7 of the 8 SF36 QoL domains, effect size >-0.5 for the domains of Physical Function and Emotional Role. @entity7047 @entity1 demonstrated significant improvement in PRWD, @entity1479 and MWD. @entity7047 was associated with a positive effect size in the SF36 index and in 2 SF36 QoL domains but a negative effect size in a further 2 domains. However, all QoL effect sizes following @entity7047 were < +/-0.5. Intergroup differences in effect sizes were >0.5 for the SF36 domains of Physical Function, Physical Role, Emotion Role and SF36 index. @entity7047 resulted in a 0.027 quality adjusted life year (QALY) gain over @entity910 in the first year post-treatment thus the cost/QALY gained of @entity7047 is pound1780 at 1 year. CONCLUSIONS: Compared to @entity910 , @entity7047 increases walking distances, improves QoL and is a highly cost-effective treatment for @entity613 .

title: A non-randomised controlled trial of the clinical and cost effectiveness of a Supervised Exercise Programme for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS', 'men']

entities_list: @entity910 :: ('MESH:D004409', 'Disease') :: ['CMT', 'conservative medical therapy']

entities_list: @entity613 :: ('MESH:D007383', 'Disease') :: ['claudication', 'intermittent claudication', 'IC']

entities_list: @entity7047 :: ('MESH:D001250', 'Disease') :: ['supervised exercise programme', 'SEP']

answer: @entity613 :: (MESH:D007383,Disease) :: ['claudication']


abstract: BACKGROUND: Whether the addition of @entity1161 ( @entity1161 ) improves overall survival in @entity1 with locally advanced @entity263 managed with @entity342 deprivation therapy (ADT) is unclear. Our aim was to compare outcomes in such @entity1 with locally advanced @entity263 . METHODS: @entity1 with: locally advanced (T3 or T4) @entity263 (n=1057); or organ-confined disease (T2) with either a @entity1486 (PSA) concentration more than 40 ng/mL (n=119) or PSA concentration more than 20 ng/mL and a Gleason score of 8 or higher (n=25), were randomly assigned (done centrally with stratification and dynamic minimisation, not masked) to receive lifelong ADT and @entity1161 (65-69 Gy to the prostate and seminal vesicles, 45 Gy to the pelvic nodes). The primary endpoint was overall survival. The results presented here are of an interim analysis planned for when two-thirds of the events for the final analysis were recorded. All efficacy analyses were done by intention to treat and were based on data from all @entity1 . This trial is registered at controlledtrials.com as ISRCTN24991896 and Clinicaltrials.gov as NCT00002633. RESULTS: Between 1995 and 2005, 1205 @entity1 were randomly assigned (602 in the ADT only group and 603 in the ADT and @entity1161 group); median follow-up was 6  0 years (IQR 4  4-8  0). At the time of analysis, a total of 320 @entity1 had died, 175 in the ADT only group and 145 in the ADT and @entity1161 group. The addition of @entity1161 to ADT improved overall survival at 7 years (74%, 95% CI 70-78 vs 66%, 60-70; hazard ratio [HR] 0  77, 95% CI 0  61-0  98, p=0  033). Both @entity137 and health-related quality-of-life results showed a small effect of @entity1161 on late gastrointestinal @entity137 (rectal bleeding grade >3, three @entity1 (0  5%) in the ADT only group, two (0  3%) in the ADT and @entity1161 group; @entity294 grade >3, four @entity1 (0  7%) vs eight (1  3%); urinary @entity137 grade >3, 14 @entity1 (2  3%) in both groups). INTERPRETATION: The benefits of combined modality treatment--ADT and @entity1161 --should be discussed with all @entity1 with locally advanced @entity263 . FUNDING: Canadian @entity5 Society Research Institute, US National @entity5 Institute, and UK Medical Research Council.

title: Combined @entity342 deprivation therapy and @entity1161 for locally advanced XXXX : a randomised, phase 3 trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'men']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

entities_list: @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation therapy', 'RT']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea']

entities_list: @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']

entities_list: @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']


abstract: OBJECTIVE: To study the epidemiology of @entity4963 and to identify risk factors for mortality among adult @entity1 MATERIAL AND METHOD: Retrospective analysis of @entity1 with @entity4963 in a 2400-bed tertiary-care university hospital in Bangkok, Thailand from June 2006 to May 2009. RESULTS: During the study period, 147 @entity1 (50% male) with clinically significant @entity4963 were identified, with a mean age of 61 years. The underlying conditions included @entity177 (47%), abdominal surgery within 30 days (31%), @entity6 (27%), @entity1583 (25%), solid @entity5 (25%), @entity1398 (23%), and @entity409 (11%). Nearly all @entity1 (98%) received antibacterial therapy within 30 days. The four most common Candida species were @entity5132 (39%), @entity9841 (28%), @entity7408 (22%) and @entity7409 (6%). Only sixty-nine @entity1 (47%) received appropriate antifungal therapy within 72 hours. The 28-day all-cause mortality was 59%. By multivariate analysis, the independent risk factors associated with mortality were @entity1398 from chemotherapy OR = 9.12 (2.94-28.31), @entity326 OR = 3.66 (1.54-8.66), ICU admission OR = 3.18 (1.27-7.92), inappropriate antifungal therapy within 72 hours OR = 2.38 (1.07-5.28) and @entity177 OR = 2.34 (1.07-5.13). CONCLUSION: Adult @entity1 with @entity4963 had a high mortality rate particularly those receiving an inappropriate antifungal therapy. Empirical antifungal therapy should be considered in selected @entity1 on the basis of underlying conditions, severity of illness and risk factors for mortality.

title: XXXX in Siriraj Hospital: epidemiology and factors associated with mortality.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity326 :: ('MESH:D012772', 'Disease') :: ['septic shock']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies']

entities_list: @entity4963 :: ('MESH:D058387', 'Disease') :: ['candidemia']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver disease']

entities_list: @entity7409 :: ('5480', 'Species') :: ['C. parapsilosis']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematologic malignancies']

answer: @entity4963 :: (MESH:D058387,Disease) :: ['Candidemia']


abstract: In Austria still more than 50% of overall mortality are due to @entity65 . An efficient prevention via change of life-style has been proven. We started with an intervention-trial in a Viennese insurance company. 667 @entity1 (50.7% m, 49.1% f, 0.1% no declaration) participated in the basic examination. The mean @entity165 level was 221.85 +/- 43.87 mg/dl, being clearly above the threshold value of 200 mg/dl. In spite of the fact, that 69.7% of the female and 65.5% of the male had elevated serum @entity165 only 1.8% already took lipid lowering drugs. @entity1 with a positive family history ( @entity583 ) had significantly elevated @entity165 (228.2 +/- 49.4 mg/dl vs 219.7 +/- 50.4 mg/dl). Another point we were drawing special attention to was the knowledge of the @entity1 about the risk factors of @entity731 . Only 13% of the males and 13.8% of the females knew their @entity165 level. 11.5% of the males and 15.9% of the females were aware of the threshold value of @entity165 . Intervention strategies (information campaign, works kitchen) have been initiated. A possible beneficial effect will be examined in biannual follow-up examinations.

title: [Risk factors of XXXX and awareness of risk in employees of a Viennese insurance company].

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Participants', 'persons']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular diseases']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity731 :: (MESH:D050197,Disease) :: ['atherosclerosis']


abstract: INTRODUCTION: The aim of this study was to assess efficacy and safety of @entity3446 (SIR) in heart transplant recipients to prevent further development of @entity453 (TxCAD) already confirmed by using coronary angiography. MATERIAL AND METHODS: We performed a retrospective case-control study involving all 60 heart transplant recipients receiving SIR in a number of combinations with other immunosuppressive drugs, and 60 matched individuals after heart transplantation treated without SIR. TxCAD was diagnosed using elective coronary angiography in 9 subjects in the study group (8 males and 1 female) of mean age 44 +/- 11 years, including @entity296 in 4 members. The control group of 15 individuals 15 males of mean age 47 +/- 7 years, including @entity296 in 8. We compared time to develop significant TxCAD and @entity204 caused by TxCAD, and all-cause @entity204 . Significance was assessed using log-rank and chi-square tests, when applicable. RESULTS: Significant TxCAD (critical coronary lesions, @entity583 or @entity204 ) was observed in 5 (56%) @entity1 receiving SIR and 11 (73%) without SIR (P = not significant [NS]). Time to develop significant TxCAD was comparable. There were 2 (22%) @entity204 in the SIR group and 8 (53%) in the control group (P = NS). Survival time was significantly longer among subjects receiving SIR (P = .02). None of @entity204 in the study group was caused by TxCAD compared with 6 (40%) @entity204 among controls (P = .09). Time of freedom from @entity204 caused by TxCAD was significantly longer in the study group (P = .023). CONCLUSION: SIR prolonged survival in heart transplant recipients with TxCAD confirmed using coronary angiography.

title: Survival benefit in heart transplant recipients who have XXXX confirmed using angiography and are receiving @entity3446 .

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['ischemic cardiomyopathy']

entities_list: @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['death', 'deaths']

answer: @entity453 :: (MESH:D003324,Disease) :: ['coronary artery disease']


abstract: BACKGROUND: The presence of effusion/ @entity3509 in pediatric pneumonia can increase treatment complexity by possibly requiring pleural drainage. Currently, no data support the superiority of any drainage modalities in @entity1 . METHODS: We performed a retrospective cohort study using the Pediatric Health Information System database from 2003 to 2008. RESULTS: A total of 14,936 @entity1 were hospitalized with effusion/ @entity3509 . Fifty-two percent of @entity1 were treated with antibiotics alone. Compared with @entity1 receiving a chest tube, patients receiving antibiotics alone, thoracotomy, and video-assisted thoracoscopic surgery had a shorter length of stay, lower mortality rates, and fewer re-interventions. Delaying drainage by 1 to 3 days was associated with a lower mortality rate, and a delay of more than 7 days was associated with a higher mortality rate. CONCLUSIONS: Half of all @entity1 with effusion/ @entity3509 are treated with antibiotics alone with low morbidity and mortality. Initial video-assisted thoracoscopic surgery or thoracotomy had improved outcomes compared with other interventions. Intervention should not be delayed beyond 7 days.

title: Outcomes associated with type of intervention and timing in complex pediatric XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'children']

answer: @entity3509 :: (MESH:D004653,Disease) :: ['empyema']


abstract: BACKGROUND: The aim of this study was to identify factors for differentiating @entity19355 from @entity293 ( @entity293 ) and to describe a cohort of @entity1 diagnosed with @entity19355 and sterile @entity4658 . METHODS: The medical records of @entity1 diagnosed with @entity19355 or @entity293 were examined. Multivariate analysis was performed to identify factors associated with @entity293 . Demographic and clinical variables were compared between @entity1 who had @entity19355 with or without sterile @entity4658 . RESULT: There were 301 @entity1 included: 158 in the roseola group (21, 13.3% with sterile @entity4658 ) and 143 in the @entity293 group. The relative risk of @entity293 over @entity19355 : increased with @entity491 (white blood cell [WBC] count >10,000/mm(3), odds ratio [OR] = 85.62) and @entity4658 (OR = 18.97); decreased with age (OR = 0.90); increased in @entity1 (OR = 2.48); increased with WBC count 4000-10,000/mm(3) (OR = 4.24); and decreased with duration of @entity221 (OR = 0.84). There was a significantly higher proportion of @entity1 in the @entity4658 group (81.0%) compared with the no @entity4658 group (44.5%, P = 0.002). A significantly higher proportion of @entity1 in the @entity4658 group (76.2%) received antibiotics than @entity1 in the no @entity4658 group (38.0%, P = 0.002). CONCLUSION: Leukocytosis is the strongest predictor of @entity293 over @entity19355 . Sterile @entity4658 may occur in @entity1 with @entity19355 .

title: Differentiating XXXX with @entity4658 from @entity293 .

entities_list: @entity1 :: ('9606', 'Species') :: ['boys', 'infants', 'girls']

entities_list: @entity4658 :: ('MESH:D011776', 'Disease') :: ['roseola pyuria', 'pyuria']

entities_list: @entity491 :: ('MESH:D007964', 'Disease') :: ['leukocytosis']

entities_list: @entity19355 :: ('MESH:D005077', 'Disease') :: ['roseola infantum']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary tract infection', 'UTI']

answer: @entity19355 :: (MESH:D005077,Disease) :: ['roseola infantum']


abstract: AIMS: Secondhand smoke (SHS) exposure is associated with elevated CHD risks. Yet the pathways through which this may operate have not been investigated in epidemiologic studies with objective SHS exposure measures and a wide range of CHD risk factors associated with active smoking. Therefore we investigate associations between SHS exposure and CHD risk factors, to clarify how SHS exposure may raise risk of CHD. METHODS: Cross-sectional population-based study of 5029 @entity1 and @entity1 aged 59-80 years from primary care practices in Great Britain. Smoking, behavioural and demographic information was reported in questionnaires; nurses made physical measurements and took blood samples for analysis of serum @entity4874 and markers of @entity32 , hemostasis and @entity409 . RESULTS: Active cigarette smokers had lower albumin and higher @entity1674 , CRP, @entity650 , white cell count, fibrinogen, blood viscosity, factor VIII, @entity2881 and @entity3479 than non-smokers. Among non-smokers, serum @entity4874 levels were independently positively associated with CRP, fibrinogen, factor VIII, @entity2881 and @entity3479 and inversely associated with albumin, after adjustment for age, gender, social and behavioural factors. The differences in CRP, fibrinogen and albumin between @entity4874 < or =0.05 and >0.7 ng/ml were one-third to one half the size of differences between @entity4874 < or =0.05 ng/ml and current smokers, but were of similar magnitude for @entity2881 and @entity3479 . CONCLUSIONS: Endothelial, inflammatory and haemostatic markers related to CHD risk showed independent associations with SHS exposure in the same direction as those for active smoking. Results aid understanding of the associations between SHS exposure and elevated CHD risks.

title: Secondhand smoke (SHS) exposure is associated with circulating markers of XXXX and endothelial function in adult @entity1 and @entity1 .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction']

entities_list: @entity4874 :: ('MESH:D003367', 'Chemical') :: ['cotinine']

answer: @entity32 :: (MESH:D007249,Disease) :: ['inflammation']


abstract: OBJECTIVE: To validate a back-specific instrument for functional assessment in the young athlete for clinical and research purposes, the @entity177 ( @entity177 ). DESIGN: Prospective cohort study, Diagnostic Level II. SETTING: Division of Sports Medicine Clinic, @entity1 's Hospital Boston. @entity1 : Male and female @entity1 aged 12 to 22 with and without @entity1643 . INTERVENTIONS: @entity1 presenting with @entity615 were compared with a control group of @entity1 presenting with complaints other than @entity615 . Both groups were given the modified Oswestry Low Back @entity158 Disability Questionnaire (ODQ) and @entity177 . MAIN OUTCOME MEASURES: @entity177 and ODQ score correlations. RESULTS: A total of 94 @entity1 were enrolled (44 @entity1 with @entity1643 and 50 @entity1 without @entity1643 ). Ages ranged from 12 to 22 for both groups, with no differences in age (P = 0.07) or gender (P = 0.50). @entity1 with @entity615 had significantly higher ODQ scores (median, 32 points) and @entity177 scores (median, 47 points) compared with controls (median, 0 points; P < 0.0001). These results held for male and female @entity1 and younger (12-16.99 years) and older (17-22 years) age groups. The Pearson correlation coefficient showed a high positive correlation between @entity177 scores and ODQ scores (Pearson r = 0.90, P < 0.0001). Cronbach level indicated excellent item reliability on the @entity177 (a = 0.904, P < 0.0001). CONCLUSIONS: The @entity177 is a valid instrument for assessing @entity158 and functional levels in the young athlete. This scale considers @entity158 , athletic function, and @entity717 .

title: Validation of a new instrument for evaluating XXXX in the young athlete.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Children', 'PARTICIPANTS']

entities_list: @entity1643 :: ('MESH:D017116', 'Disease') :: ['low back pain']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['Micheli Functional Scale', 'MFS']

entities_list: @entity615 :: ('MESH:D001416', 'Disease') :: ['back pain']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['athletic disability']

answer: @entity1643 :: (MESH:D017116,Disease) :: ['low back pain']


abstract: PURPOSE: @entity1125 (BTC) is a dismal disease with no standard chemotherapy. We investigated efficacy and @entity137 of biweekly @entity901 with 48-h infusion of @entity1487 /LV in advanced BTC. METHODS: All @entity1 had histologic confirmation of BTC, at least one measurable site of disease, and had received no prior chemotherapy. @entity1 were older than 20 years with ECOG performance scores (PS) of 0-2. Treatment involved 2-h infusion of @entity901 (85 mg/m(2)) diluted in D5W 500 ml followed by 48-h infusion of @entity1487 (3,000 mg/m(2)) and LV (100 mg/m(2)) biweekly. Response evaluation was based on RECIST criteria and was carried out every two courses of treatment; @entity137 evaluation was based on NCI common @entity137 criteria version 3.0. RESULTS: From August 2005 to December 2006, 34 chemotherapy-naive @entity1 with advanced BTC were enrolled and 32 intention-to-treat @entity1 were evaluated. Partial response was 18.8%, stable disease was 31.3%, resulting in a disease control rate of 50.0%. Median time to progression and survival was 3.7 and 7 months, respectively. The most common grade 3/4 @entity137 were @entity1398 15.6% (5/32), @entity3136 9.4% (3/32), @entity882 6.3% (2/32), @entity294 6.3% (2/32) and @entity16 3.1% (1/32). No treatment-related @entity204 occurred. CONCLUSIONS: The biweekly OXA and 48-h infusion of @entity1487 /LV in @entity1 with advanced BTC showed tolerable and efficacy equivalent to other combination regimens treatment.

title: A phase II trial of biweekly XXXX with simplified schedule of 48-h infusion of high-dose @entity1487 and leucorvin for advanced biliary tract carcinoma.

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity1125 :: ('MESH:D001661', 'Disease') :: ['Advanced biliary tract carcinoma']

answer: @entity901 :: (MESH:C030110,Chemical) :: ['oxaliplatin']


abstract: INTRODUCTION: We define focal @entity358 (FPL) as an intra-parenchymatous @entity358 that is well circumscribed and completely surrounded by healthy lung. It is considered that the profitability of the fine needle aspiration puncture (FNAP) in FPL < or = 2 cm is better than that of the fibrobronchoscopy (FBC). OBJECTIVE: To analyze the diagnostic profitability of the FNAP in the malignant FPL and study if it varies according to site, size and histology. MATERIAL AND METHODS: We analyzed all the FBCs of our Unit between 01/2000 and 12/2001 in @entity1 with solitary FLP < or = 6 cm with a definitive diagnosis of @entity5 . The diagnostic profitability by size, site and histology was analyzed with Pearson's chi(2) statistics. RESULTS: 124 @entity1 . Mean FBC per @entity1 was 1.3. A total of 101 cases (82%) were diagnosed with FBC, 15 by thoracotomy and 8 by FNAP. Global diagnostic profitability of the FBC was 0.82 and the transbronchial biopsy 0.76. There are no diagnostic profitability differences by size (< or = 2 cm vs > 2 cm) (0.81 vs 0.82 p = 0.96), site (peripheral vs central) (0.79 vs 0.85 p = 0.41) and histology (epidermoid vs @entity420 ) (0.89 vs 0.75 p = 0.21). CONCLUSION: Profitability of the FBC in malignant FPL in our hospital is elevated without differences by size, site or histology. In our site, the initial diagnostic approach of the FLP is done with FBC.

title: [Profitability of the bronchoscopy in the diagnosis of focal XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary lesion']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy']

answer: @entity358 :: (MESH:D008171,Disease) :: ['pulmonary malignant lesions']


abstract: SUMMARY: One hundred and seventy @entity1 with @entity1756 were treated by coil embolization from September 1997 to December 2002. After January 2000, coil embolization was selected as the first-choice treatment for @entity1756 . During this period, the authors investigated the number of aborted cases, the number of complications, and how many @entity1 could be treated by coil embolization according to the locations of @entity1756 . One hundred and ninety-five sessions were performed on 170 @entity1 , and 13 sessions (6.7%) were aborted mainly because of the difficulty of the approach and the wide necks of the @entity439 . In four @entity1 , although procedural perforation and @entity548 occurred, the outcome was good or excellent. Eight poorgrade @entity1 experienced @entity548 after coil embolization and seven @entity1 died. The volume embolization ratios of small and large @entity439 were 27% and 21%, and the recanalization of small and large @entity439 occurred in 9% and 38% of @entity1 , respectively. From January 2000 to December 2002, 119 (66%) of 180 @entity1756 were treated by coil embolization. According to the location of @entity439 , 89% vertebrobasilar, 87% anterior cerebral, 65% internal carotid and 24% middle cerebral @entity438 could be treated by coil embolization. Because the tight packing of large @entity439 was difficult, the recanalization rate of large @entity439 was high. However, the results of small @entity439 were satisfactory. Almost 90% of vertebrobasilar and anterior cerebral @entity438 could be treated by coil embolization.

title: Endovascular surgery as the first-choice treatment for XXXX : how far has it come?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['haemorrhage']

entities_list: @entity1756 :: ('MESH:D017542', 'Disease') :: ['ruptured aneurysms', 'ruptured cerebral aneurysms']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['artery aneurysms']

answer: @entity1756 :: (MESH:D017542,Disease) :: ['ruptured cerebral aneurysms']


abstract: AIM: To study an association between @entity3885 ( @entity1030 ) and @entity565 and types 1 and 2 @entity6 (T1D and @entity2175 ). SUBJECTS AND METHODS: A multicenter study was conducted in two formed cohorts of @entity1 with bronchopulmonary pathology (n = 616) and @entity6 (n = 700). Random sampling, retrospective data collection, by applying a blind approach, as well as questioning and, if need be, diagnosis verification and an additional study were accomplished. Statistical methods were employed to make a cross assessment of the prevalence of the diseases in each cohort as compared to a control group in which population-based values were used. RESULTS: In the cohort of @entity1 with bronchopulmonary pathology, the prevalence of @entity2175 was considerable in @entity1 with @entity1030 , it was 9.49%, which was greater than the control values (3.0; p < 0.01), more than 25 times higher (p < 0.05) than that in @entity748 @entity1 in whom the prevalence was 3.64% and it did not differ from the control group. In @entity1030 concurrent with @entity2175 , the prevalence of @entity6 was as high as 16.15% (p < 0.001). At the same time, the prevalence of bronchopulmonary pathology in the @entity2175 cohort being 2.3% for @entity1030 and 1.0% for @entity565 was lower than the population-based value (p < 0.05), 2.6% and 6.1%, respectively. It was contrastingly found that T1D was absent in the @entity748 @entity1 and the prevalence of @entity565 (0.33%) was low in @entity1 with @entity565 (p < 0.05). In parallel, an association between @entity1030 and T1D could not be traced, by taking into account an age difference and other specific features of a pathological process in these @entity1 groups. CONCLUSION: Unlike @entity565 , @entity1030 , in combination with @entity565 in particular, is an essential risk factor for @entity2175 . Asthma and T1D mutually exclude each other.

title: [Association between chronic @entity3885 and XXXX , type I and II].

entities_list: @entity748 :: ('MESH:D013224', 'Disease') :: ['asthmatic']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity3885 :: ('MESH:D008173', 'Disease') :: ['multifactorial obstructive pulmonary disease']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes mellitus']


abstract: Objectives. The study was conducted to determine the correlation of @entity2071 , @entity4725 , and anti- @entity6300 antibody levels with @entity1252 ( @entity1252 ) and standard @entity1252 activity immunological markers (anti-dsDNA and sera C3 and C4). Study Design. This was a cross-sectional study. Materials and Methods. Blood samples were obtained from 95 @entity1252 @entity1 (45 active @entity1252 and 50 nonactive @entity1252 ) and 50 controls. The subjects were assessed using @entity1252 and score of more than five is determined as having active @entity1252 . The sera were tested for serum @entity2071 , @entity4725 , and anti- @entity6300 (ELISA), anti-dsDNA (CLIFT), serum C3, and serum C4 (immunonephelometry). Results. Anti-dsDNA and anti- @entity6300 antibody showed good positive correlations with @entity1252 (r = 0.529, P < 0.001 and r = 0.559, P < 0.001, resp.). @entity4725 and sera C3 and C4 showed fair correlation with @entity1252 (r = 0.294, P = 0.004; r = -0.312, P = 0.002; and r = -0.382, P < 0.001, resp.). @entity2071 level showed no significant correlation with @entity1252 (P = 0.062). There were significant correlations of @entity4725 and anti- @entity6300 antibody with anti-dsDNA (r = 0.226, P = 0.006 and r = 0.511, P < 0.001, resp.). @entity4725 showed poor inverse correlation with serum C3 (r = -0.183, P = 0.028) and fair inverse correlation with serum C4 (r = -0.251, P = 0.002). Anti- @entity6300 antibody demonstrated fair inverse correlation with both sera C3 and C4 (r = -0.420, P  <= 0.001 and r = -0.398, P < 0.001, resp.). However, @entity2071 showed no significant correlation with anti-dsDNA and sera C3 and C4 (P = 0.259, P = 0.626 and P = 0.338, resp.). Conclusions. The serum levels of anti- @entity6300 antibody in @entity1252 @entity1 showed the best correlation with the @entity1252 and standard immunological tests for @entity1252 activity. These data support that anti- @entity6300 antibody is a useful marker for monitoring @entity1252 global disease activity. The potential of @entity4725 needs further confirmation.

title: The Usefulness of Endothelial Cell Adhesion Molecules and Anti- XXXX Antibody in Monitoring Systemic Lupus Erythematosus Disease Activity.

entities_list: @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'SLEDAI', 'SLE disease activity index', 'SLE disease']

answer: @entity6300 :: (712,Gene) :: ['C1q']


abstract: This study assessed relationships among @entity62 ( @entity62 ), cerebrospinal fluid (CSF), @entity195 ( @entity195 ) pathology markers, and brain volume loss. Subjects included 197 controls, 331 individuals with @entity73 ( @entity73 ), and 146 individuals with @entity195 with serial volumetric 1.5-T MRI. CSF Ab1-42 (n = 351) and tau (n = 346) were measured. Brain volume change was quantified using the boundary shift integral (BSI). We assessed the association between baseline @entity62 volume and annualized BSI, adjusting for intracranial volume. We also performed multiple regression analyses in the CSF subset, assessing the relationships of @entity62 and Ab1-42 and/or tau with BSI. @entity62 burden was positively associated with BSI in controls (p = 0.02) but not @entity73 or @entity195 . In multivariable models, @entity62 (p = 0.003) and Ab1-42 (p = 0.001) were independently associated with BSI in controls; in @entity73 Ab1-42 (p < 0.001) and tau (p = 0.04) were associated with BSI. There was no evidence of independent effects of @entity62 or CSF measures on BSI in @entity195 . These data support findings that @entity1504 is associated with increased @entity1010 in the context of @entity195 pathology in pre- @entity303 stages.

title: Vascular and XXXX markers independently predict @entity1010 rate in @entity195 Neuroimaging Initiative controls.

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['MCI', 'mild cognitive impairment']

entities_list: @entity1504 :: ('MESH:D002561', 'Disease') :: ['vascular damage']

entities_list: @entity1010 :: ('MESH:C566985', 'Disease') :: ['brain atrophy']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's disease"]

entities_list: @entity62 :: ('MESH:D056784', 'Disease') :: ['WMH', 'white matter hyperintensities']

answer: @entity195 :: (MESH:D000544,Disease) :: ['Alzheimer's disease']


abstract: BACKGROUND: Highly crosslinked UHMWPE is associated with increased wear resistance in hip simulator and clinical studies. Laboratory and case studies, however, have described rim @entity174 in crosslinked acetabular liners. Controversy exists, therefore, on the relative merits of crosslinked liners over conventional liners in terms of wear performance versus resistance to fatigue cracking. QUESTIONS/PURPOSES: We asked whether crosslinked liners would show less surface damage than conventional liners but would be more susceptible to @entity16 . METHODS: We examined 36 conventional UHMWPE and 39 crosslinked UHMWPE retrieved implants with similar @entity1 demographics and identical design for evidence of @entity16 , including articular surface damage, impingement, screw-hole creep, and rim cracks. RESULTS: We observed no difference in @entity16 scores for the two liners. Conventional liners more frequently impinged but were more often elevated with smaller head sizes. We observed creep in approximately 70% of both types of liners. Incipient rim cracks were found in five crosslinked liners, and one liner had a rim @entity174 . Only one conventional liner had an incipient rim crack. CONCLUSIONS: Contrary to our expectation, damage was similar between crosslinked and conventional UHMWPE liners. Moreover, the 15% occurrence (six of 39) of @entity174 in crosslinked liners as compared with a 3% occurrence (one of 36) in conventional liners may have implications for the long-term performance of crosslinked liners. Longer-term studies will be necessary to establish the fate of rim cracks and thus the overall clinical fatigue performance of crosslinked liners.

title: Retrieved highly crosslinked UHMWPE acetabular liners have similar XXXX as conventional UHMWPE.

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['wear damage', 'fatigue damage']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture', 'incipient or complete fractures']

answer: @entity16 :: (MESH:D009422,Disease) :: ['wear damage']


abstract: BACKGROUND: Search and rescue helicopters from the French navy conduct ambulance and search and rescue missions near the western coast of the French Britain. The team on board includes military doctor and paramedic. Operations in this area are challenging due to long distances and severe weather conditions. METHODS: We studied retrospectively 205 search and rescue missions from 2000 to 2007 with special emphasis on @entity299 and operative conditions. RESULTS: 12.2% of the missions (25/205) concern @entity299 dominated by @entity583 elevation @entity583 . All of the @entity1 are male. Most of them are seafarers and the others come from ferries with a median age of 53.4 years. Sixty-two percent of the missions were carried in darkness. The median range is about 80 nautical miles. Two @entity1 died during search and rescue missions. All @entity1 are hospitalized. CONCLUSION: Ambulance and search and rescue mission near the western coasting of the French Britain are a challenge. Using a heavy helicopter from French Navy was the best way to carry medical treatment to seafarers and passengers of ferries suffering from @entity299 .

title: [Acute XXXX in search and rescue helicopter missions, from French Navy. A retrospective study from 2000 to 2007].

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'patients']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['acute heart disease']

answer: @entity299 :: (MESH:D006331,Disease) :: ['heart disease']


abstract: CONTEXT: @entity1575 occurs in response to several aggressive agents and is a predisposing factor in @entity82 . @entity4059 were shown to stimulate liver growth and to restore the histological architecture of the liver. They also cause an improvement in liver function and accelerate the reversion of @entity82 before it progresses to @entity82 . OBJECTIVE: To test the effects of @entity1575 solution composed by @entity1522 , vitamins, @entity413 , insulin, glucagon and @entity1954 on @entity1575 in @entity35 . METHODS: @entity82 was induced in @entity35 by gastric administration of @entity1232 (10 mg/kg) for 5 weeks. After liver biopsy, the @entity35 received either hepatotrophic factors solution (40 mg/kg/day) or saline solution for 10 days by intraperitoneal injection. Blood samples and liver fragments were collected for hepatic function analysis, standard histopathology evaluation, and morphometric collagen quantification. RESULTS: @entity35 in the hepatotrophic factors group showed a decrease of the histopathological components of @entity82 and an increase of their hepatic mass (12.2%). There was no development of @entity75 in both groups. Compared with the saline group, the hepatotrophic factors group also had a decrease of blood levels of @entity99 markers (AST, ALT) and a decrease of collagen content in the portal spaces (31.6%) and perisinusoidal spaces (42.3%), as well as around the hepatic terminal vein (57.7%). Thus, hepatotrophic factors administration in the portal blood promoted a regenerative hepatic response, with an overall reduction of the volumetric density of collagen, improved hepatic function, and a general improvement in the histopathological aspects of @entity82 . CONCLUSION: Taken together, these results suggest the potential therapeutic use of this hepatotrophic factors solution to treat chronic @entity409 .

title: XXXX reduce @entity1575 in @entity35 .

entities_list: @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis', 'cirrhosis', 'Fibrosis']

entities_list: @entity4059 :: ('MESH:D007020', 'Disease') :: ['Hepatotrophic factors']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['neoplasic lesions']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver diseases']

entities_list: @entity1575 :: ('MESH:D008103', 'Disease') :: ['hepatic fibrosis', 'Hepatic fibrosis']

entities_list: @entity1232 :: ('MESH:D004128', 'Chemical') :: ['dimethylnitrosamine']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic-lesion']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity1954 :: ('MESH:D014284', 'Chemical') :: ['triiodothyronine']

answer: @entity4059 :: (MESH:D007020,Disease) :: ['Hepatotrophic factors']


abstract: OBJECTIVE: This study was aimed to investigate the characteristics of coronary artery @entity460 (CAC) in Chinese population with @entity453 ( @entity453 ). METHODS: We studied 205 Chinese @entity1 with @entity453 who were subjected to combined MPI and CAC score (CACS) study on a hybrid single photon emission tomography/computed tomography (SPET/CT) scanner. RESULTS: a) Among the 205 @entity1 132 (64.3%) had CACS=0 and 73 (35.6%) had CACS>0. Of those with CACS>0, 58 (28.3%) had CACS of 1   399 and 15 (7.3%) had CACS>= 400. b) The prevalence of CAC and CACS increased significantly with age (P<0.05). c) Age and @entity101 were independent risk factors for CAC. d) The incidence of @entity63 MPI for all 205 @entity1 was 10.6% (14/132), 19.0% (11/58) and 33.3% (5/15). For @entity1 with CACS=0, of 1   399 and >= 400, respectively, showing significant difference (P=0.034), and significantly increased with CACS increasing (P=0.010). The incidence of @entity63 MPI increased with increasing CACS from 10.6% (CACS=0) to 33.3% (CACS>= 400). e) CACS was weakly correlated or not correlated. The value of the correlation coefficient was very small, P value was less than 0.05 with @entity63 MPI (r=0.164, P=0.019) but the accuracy of the presence of CAC for detecting @entity63 MPI was only 65.4% (134/205). f) The area under the ROC curve was 0.615 (P<0.05, 95% CI: 0.500   0.729). CONCLUSION: Compared with western populations, the prevalence of CAC and absolute CACS in Chinese population with intermediate likelihood of CAD was low. CACS was weakly correlated with @entity63 MPI, the accuracy of the presence of CAC for predicting @entity63 MPI was low. CACS was not a reliable screening tool prior to MPI in Chinese @entity1 with @entity453 .

title: Characteristics of coronary artery @entity460 and its relationship to myocardial ischemia in Chinese XXXX with @entity453 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['SCAD', 'suspected coronary artery disease']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: We report a 48-year-old female who presented limb-girdle type @entity1737 with @entity55 and @entity309 . She demonstrated a rapidly progressive @entity425 of @entity1746 . Neurological examination revealed @entity425 , and proximal dominant limb @entity2057 and @entity425 . @entity1736 , @entity4610 , and @entity10296 were not observed. The @entity4560 test and serum anti- @entity934 receptor antibody were positive. The repetitive nerve stimulation showed 55% waning in the thenar muscles. From these findings, she was diagnosed as having @entity1737 . Plain chest X-P and body CT showed @entity5 -like lesions in the lung. Lung biopsy revealed the infiltration of lymphocytes. These lesions decreased in size after thymectomy and corticosteroid administration. Immediately after thymectomy, she began to have morning stiffness with @entity158 . RAHA test, which was negative before thymectomy, became highly positive. These findings were consistent with @entity309 . In this @entity1 , thymus probably played a role to suppress the development of @entity309 .

title: [A case of limb-girdle type @entity1737 in whom XXXX appeared immediately after thymectomy].

entities_list: @entity4560 :: ('MESH:D004491', 'Chemical') :: ['edrophonium']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['inflammatory lung lesions']

entities_list: @entity10296 :: ('MESH:D010244', 'Disease') :: ['bulbar palsy']

entities_list: @entity1737 :: ('MESH:D009157', 'Disease') :: ['myasthenia gravis']

entities_list: @entity1746 :: ('MESH:D020335', 'Disease') :: ['extremities']

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['muscle weakness', 'weakness', 'facial muscle weakness']

entities_list: @entity4610 :: ('MESH:D009886', 'Disease') :: ['ophthalmoplegia']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain and swelling of the finger and knee joints']

entities_list: @entity2057 :: ('MESH:D009133', 'Disease') :: ['muscle atrophy']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']


abstract: Mesenchymal stem cells (MSCs) have shown great potential in regenerative medicine. Sensitive and reliable methods for stem cell labeling and in vivo tracking are thus of great importance. Herein, we report the use of upconversion nanoparticles (UCNPs) as an exogenous contrast agent to track @entity19 MSCs (mMSCs) in vivo. To improve the labeling efficiency, oligo- @entity369 is conjugated to @entity968 ( @entity970 ) coated UCNPs to enhance the nanoparticles uptake by mMSCs. Systematic in vitro tests reveal that the proliferation and differentiation of mMSCs are not notably affected by UCNP-labeling, suggesting that the labeled cells are able to maintain their stem cell potency. No apparent exocytosis is found in our in vitro labeling experiment by using a transwell culture system over a course of 10 days, indicating the potential capability of using our UCNP-labeling method for long-term stem cell tracking. To demonstrate the tracking sensitivity of our stem cell labeling approach, UCNP-labeled mMSCs are subcutaneously transplanted into @entity19 and imaged using an in vivo upconversion luminescence (UCL) imaging system. As few as ~10 cells labeled with UCNPs are detected in vivo, evidencing a remarkable improvement in detection sensitivity of our UCNP-labeled hMSCs compared with other stem cell labeling techniques using conventional exogenous agents. We further track UCNP-labeled mMSCs after intravenous injection, and observe the translocation of mMSCs from lung where they initially accumulate, to liver, a phenomenon consistent to previous reports. Our results highlight the promise of using UCNPs as a new type of ultra-sensitive probes for labeling and in vivo tracking of stem cells at nearly the single cell level.

title: Towards whole-body imaging at the single cell level using ultra-sensitive stem cell labeling with oligo- XXXX modified upconversion nanoparticles.

entities_list: @entity369 :: ('CHEBI:29016', 'Chemical') :: ['arginine']

entities_list: @entity968 :: ('MESH:D011092', 'Chemical') :: ['polyethylene glycol']

answer: @entity369 :: (CHEBI:29016,Chemical) :: ['arginine']


abstract: The presence of @entity969 (Suc) in plastids was questioned for several decades. Although it was reported some decades ago, neither Suc transporters nor Suc metabolizing enzymes were demonstrated to be active in those organelles. By biochemical, immunological, molecular and genetic approaches we show that alkaline/neutral invertases (A/N-Invs) are also localized in chloroplasts of @entity2772 and @entity958 . A/N-Inv activity and polypeptide content were shown in protein extracts from intact chloroplasts. Moreover, we functionally characterized the @entity958 At-A/N-InvE gene coding for a chloroplast-targeted A/N-Inv. The At-A/N-InvE knockout plants displayed a lower total A/N-Inv activity in comparison with wild-type plants. Furthermore, neither A/N-Inv activity nor A/N-Inv polypeptides were detected in protein extracts prepared from chloroplasts of mutant plants. Also, the measurement of @entity1735 content, in leaves harvested either at the end of the day or at the end of the night period, revealed that the knockout plants showed a decrease in starch accumulation but no alteration in Suc levels. These are the first results demonstrating the presence of a functional A/N-Inv inside chloroplasts and its relation with @entity505 storage in @entity958 leaves. Taken together our data and recent reports, we conclude that the participation of A/N-Invs in the @entity505 flux between the cytosol and the plastids may be a general phenomenon in plants.

title: New insights on @entity969 metabolism: evidence for an active A/N-Inv in chloroplasts uncovers a novel component of the intracellular XXXX trafficking.

entities_list: @entity958 :: ('3702', 'Species') :: ['Arabidopsis']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

entities_list: @entity969 :: ('MESH:D013395', 'Chemical') :: ['sucrose']

answer: @entity505 :: (MESH:D002244,Chemical) :: ['carbon']